Scholarlink

Background <p>Mirikizumab, a monoclonal antibody targeting interleukin-23 (IL-23), was studied for adult patients with moderate-to-severe inflammatory bowel disease (IBD). However, conflicting evidence exists on its safety, efficacy and optimal dosing strategy.</p> Aim <p>To evaluate the safety and efficacy of mirikizumab in treating IBD and understand a dose–response relationship based on clinical, endoscopic, and histological outcomes.</p> Methodology <p>A systematic search of six electronic databases, i.e. PubMed, ClinicalTrials.gov, Cochrane CENTRAL, ScienceDirect, ProQuest, and EBSCO, was conducted (PROSPERO: CRD42024570804). Relevant data were extracted from selected studies. Primary endpoints included safety, efficacy, adverse events (AEs), serious adverse events (SAEs), and mortality. Dose–response relationship was assessed as a secondary endpoint.</p> Results <p>Six trials were eligible from 415 screened records, pooling 3,990 participants (3,073 of whom received mirikizumab). Mirikizumab significantly improved clinical remission (relative risk [RR] [95% CI] = 1.87 [1.57–2.22]) and histological outcomes (RR [95% CI] = 1.63 [1.35–1.97]) with minimal heterogeneity across subgroups, i.e. intravenous (IV) and subcutaneous (SC) routes. The drug significantly improved endoscopic remission (RR [95% CI] = 1.66 [1.28–2.16]), particularly with IV route (RR = 2.09). The risk for AEs was similar between groups, with low heterogeneity (I<sup>2</sup> = 2.0%).</p> Conclusion <p>Mirikizumab improves clinical, histological, and endoscopic outcomes in IBD with a favorable safety profile. There was no significant difference with different injection routes and with incrementing dose beyond 200&#xa0;mg.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Safety and efficacy of mirikizumab as induction and maintenance for inflammatory bowel disease in adult patients: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月21日

查看全文
  • Maryam Falah,
  • Leen Alhamd,
  • Fatma Bayoumi,
  • Aisha Allah Diwaya,
  • Enas Taha,
  • Lamia Alkodami,
  • Riham Alsutaif,
  • Bushra Mohandes,
  • Idris Sula,
  • Muhammad Candragupta Jihwaprani,
  • Fathiya El-Raey

摘要

Background

Mirikizumab, a monoclonal antibody targeting interleukin-23 (IL-23), was studied for adult patients with moderate-to-severe inflammatory bowel disease (IBD). However, conflicting evidence exists on its safety, efficacy and optimal dosing strategy.

Aim

To evaluate the safety and efficacy of mirikizumab in treating IBD and understand a dose–response relationship based on clinical, endoscopic, and histological outcomes.

Methodology

A systematic search of six electronic databases, i.e. PubMed, ClinicalTrials.gov, Cochrane CENTRAL, ScienceDirect, ProQuest, and EBSCO, was conducted (PROSPERO: CRD42024570804). Relevant data were extracted from selected studies. Primary endpoints included safety, efficacy, adverse events (AEs), serious adverse events (SAEs), and mortality. Dose–response relationship was assessed as a secondary endpoint.

Results

Six trials were eligible from 415 screened records, pooling 3,990 participants (3,073 of whom received mirikizumab). Mirikizumab significantly improved clinical remission (relative risk [RR] [95% CI] = 1.87 [1.57–2.22]) and histological outcomes (RR [95% CI] = 1.63 [1.35–1.97]) with minimal heterogeneity across subgroups, i.e. intravenous (IV) and subcutaneous (SC) routes. The drug significantly improved endoscopic remission (RR [95% CI] = 1.66 [1.28–2.16]), particularly with IV route (RR = 2.09). The risk for AEs was similar between groups, with low heterogeneity (I2 = 2.0%).

Conclusion

Mirikizumab improves clinical, histological, and endoscopic outcomes in IBD with a favorable safety profile. There was no significant difference with different injection routes and with incrementing dose beyond 200 mg.